OSU-2S/Sorafenib Synergistic Antitumor Combination against Hepatocellular Carcinoma: The Role of PKC delta/p53

doi:10.3389/fphar.2016.00463

Chia Nan University of Pharmacy & Science Institutional Repository > 藥理學院 > 生物科技系(所) > 期刊論文 > Item 310902800/31121

請使用永久網址來引用或連結此文件: https://ir.cnu.edu.tw/handle/310902800/31121

標題:	OSU-2S/Sorafenib Synergistic Antitumor Combination against Hepatocellular Carcinoma: The Role of PKC delta/p53
作者:	Omari, Hany A. Tolba, Mai F. Hung, Jui-Hsiang Al-Tel, Taleb H.
貢獻者:	Sharjah Institute for Medical Research and College of Pharmacy, University of Sharjah Department of Pharmacology and Toxicology, Faculty of Pharmacy, Beni-Suef University Department of Pharmacology and Toxicology, Faculty of Pharmacy, Ain Shams University School of Pharmacy, Chapman University, Irvine Department of Biotechnology, Chia Nan University of Pharmacy and Science
關鍵字:	OSU-2S sorafenib hepatocellular carcinoma cancer resistance PKCδ
日期:	2016-11
上傳時間:	2018-03-09 14:25:00 (UTC+8)
出版者:	Frontiers Media Sa
摘要:	Background: Sorafenib (Nexavar®) is an FDA-approved systemic therapy for advanced hepatocellular carcinoma (HCC). However, the low efficacy and adverse effects at high doses limit the clinical application of sorafenib and strongly recommend its combination with other agents aiming at ameliorating its drawbacks. OSU-2S, a PKCδ activator, was selected as a potential candidate anticancer agent to be combined with sorafenib to promote the anti-cancer activity through synergistic interaction. Methods: The antitumor effects of sorafenib, OSU-2S and their combination were assessed by MTT assay, caspase activation, Western blotting, migration/invasion assays in four different HCC cell lines. The synergistic interactions were determined by Calcusyn analysis. PKCδ knockdown was used to elucidate the role of PKCδ activation as a mechanism for the synergy. The knockdown/over-expression of p53 was used to explain the differential sensitivity of HCC cell lines to sorafenib and/or OSU-2S. Results: OSU-2S synergistically enhanced the anti-proliferative effects of sorafenib in the four used HCC cell lines with combination indices <1. This effect was accompanied by parallel increases in caspase 3/7 activity, PARP cleavage, PKCδ activation and inhibition of HCC cell migration/invasion. In addition, PKCδ knockdown abolished the synergy between sorafenib and OSU-2S. Furthermore, p53 restoration in Hep3B cells through the over-expression rendered them more sensitive to both agents while p53 knockdown from HepG2 cells increased their resistance to both agents. Conclusion: OSU-2S augments the anti-proliferative effect of sorafenib in HCC cell lines, in part, through the activation of PKCδ. The p53 status in HCC cells predicts their sensitivity toward both sorafenib and OSU-2S. The proposed combination represents a therapeutically relevant approach that can lead to a new HCC therapeutic protocol.
關聯:	Frontiers In Pharmacology, v.7, 463 p53
顯示於類別:	[生物科技系(所)] 期刊論文

文件中的檔案:

檔案	描述	大小	格式	瀏覽次數
31121.pdf		3475Kb	Adobe PDF	422	檢視/開啟
index.html		0Kb	HTML	1536	檢視/開啟

在CNU IR中所有的資料項目都受到原著作權保護.

TAIR相關文章

資料載入中.....